.The carcinogenic..petl. of. 40 (14) , which have been implicated in a variety of toxic effects (15) including cancer (initiation and promotion), especially in small rodents which have particular sensitivity to oxygen radical toxicity (11, 12) . Chemicals that act as substrates for other cytochromes P450 are, in general, detoxified by these enzymes to polar metabolites which are readily conjugated and eliminated (10) .
From a consideration of their molecular and electronic structures, chemicals may be shown to exhibit specificity for one or more of these cytochromes P450, and, together with information relating to the enzymes' active site dimensions, it is possible to accurately predict the P450 specificity of a test compound and its toxic outcome. To predict the P450 isoform, it is necessary to calculate certain molecular and electronic structural characteristics, the overall degree of planarity (area/depth2), the molecular size (collision diameter), and the likelihood of activation by oxygenation, expressed as AE, the energy difference between the lowest unoccupied and the highest occupied molecular orbits [(AE = E(LUMO) -E(HOMO); LUMO, lowest unoccupied molecular orbit; HOMO, highest occupied molecular orbit]. Graphical analysis of this information and comparison with training set data for known cytochrome P450 substrates and inducers, including carcinogens and noncarcinogens, leads to an overall prediction of potential toxicity. This technique of COMPACT (16, 17) has been validated against 100 NTP chemicals of known carcinogenicity and gave a concordance of 92% based on specificity for P4501 and P4502E (17) . The COMPACT evaluation of the 40 NTP chemicals in the present study (18) were compared with our own Hazardexpert evaluations of the same chemicals and with rodent carcinogenicity assays and Ames test results previously published (19, 20) .
Methods
Molecular structural and electronic parameters for COMPACT analysis of the 40 NTP chemicals were determined as previously described (2, 17, 18 (19, 20) . One positive response in the four segments of the rodent assay is taken as an overall "+" response. When this single response is EE (equivocal evi-A -a -e 9 * * .9-dence), the overall response is given as "±," but is taken as "-" in the final assessment. Hazardexpert evaluations were made using the standard software (version 6.1; Compudrug Ltd., Budapest) (3, 21) . Concordance evaluations are made between COMPACT predictions (C) and rodent carcinogenicity (1/4 segments positive) and between COMPACT plus Hazardexpert and rodent carcinogenicity.
Results
The outcome of COMPACT analysis on 40 of the 44 test chemicals is shown in Table 1 (18) . COMPACT predictions could not be made for 4 of these chemicals, as three were inorganic (nos. 7, 16 and 35) and one was polymeric (no. 3). (19, 20 4. Promethazine. Promethazine is positive in COMPACT, primarily due to its low AE value; it does not exhibit high planarity due to a bulky side chain and the combination of sulfur and nitrogen heteroatoms in the ring system, which becomes V-shaped. Consequently, it is unlikely to be a good P4501 substrate or inducer. Promethazine is negative in all segments of the rodent assay; consequently, there is no concordance with COMPACT.
5. Resorcinol This compound is not a likely P4501 substrate (CR = 0.70) because it has a relatively high AEvalue (15.7) and is readily conjugated. Although the COM-PACT ratio would suggest that it would be equivocally positive, in the original graphical analysis it was clearly negative (18) . Since the molecular diameter of resorcinol is 5.6, and its AE is 15.7, the COMPACT prediction for CYP2E1 is also negative. Resorcinol is negative in the rodent assay, so the COM-PACT analysis is in concordance with the biological data. Hazardexpert predicts that this compound would be mutagenic.
6. y-Butyrolactone. This compound is negative in COMPACT for P4501, and although it has a diameter characteristic of a P4502E substrate, its high AE value mitigates against ROS production and carcinogenicity. A negative finding in the rodent assay, with the exception of equivocal evidence for carcinogenicity in the male mouse, accords with the COMPACT prediction, but Hazardexpert predicts mutagenicity.
7 18 . Theophylline. The chemical is positive in COMPACT for both P4501 and P4502E and is known to exhibit specificity for P4501. However, because the rodent tests are incomplete, it is not possible to establish concordance at this stage.
19. 4,4'-Thiobis(6-t-butyl m-cresol). This compound is borderline in COM-PACT for P4501 and negative for P4502E and is therefore considered unlikely to be a carcinogen. In the rodent assay, this compound is negative, which is in concordance with the COMPACT prediction.
20. Triamterene. COMPACT clearly predicts a positive for P4501, and Nhydroxylation by P4501A2 would give rise to a nitrenium ion that could interact irreversibly with DNA. The rodent assay agrees with this for both segments of the mouse data, although the rat study is equivocal. It is considered that COM-PACT prediction is in concordance with the biological assay for this compound. Hazardexpert also predicts carcinogenicity.
21. Diphenylhydantoin (phenytoin). Phenytoin is negative for both P4501 and P4502E in COMPACT, and there is substantial biochemical evidence that it is metabolized by P4502B and C. Phenytoin is a known teratogen, but predictions for carcinogenicity are negative for both COMPACT and Hazardexpert. There is evidence of carcinogencity in 1/4 segments (female mouse) of the rodent assay. Therefore, there is no concordance between the COMPACT prediction and the findings in the rodent assay.
22. Pentachloroanisole. Pentachloroanisole is positive in COMPACT for P4501 only and may interact with the Ah receptor (involved in the induction of P4501A) because there is some degree of structural similarity with TCDD. This prediction of carcinogenicity accords with the positive results obtained in the rodent assay. Hazardexpert predicts weak carcinogenicity.
23. Chloramine. Chloramine is positive for P4501 in COMPACT and was hence predicted positive. Evidence for carcinogenicity in the rodent assay is largely negative, therefore no concordance is shown with the COMPACT prediction. However, this chemical is known to undergo rapid decomposition in solution and to be readily eliminated due to its polarity. 24 . 4,4-Diamino-2,2'-stilbenedisulfonic acid. This chemical is positive for P4501 in COMPACT, but it is probably readily eliminated due to the two sulfonic acid groups, which are both polar and ionized at physiological pH. The rodent carcinogenicity data are negative, so there is no concordance with the COMPACT pre- diction. Hazardexpert predicts teratogenicity but not carcinogenicity. 25 . Methyl bromide. COMPACT predicts P4502E specificity for this compound, and there is biochemical evidence to support this prediction. The mouse bioassay shows no carcinogenicity; no data are available for rat. The lack of P4501 specificity accords with the rodent assay, but there is no concordance between the prediction of P4502E activity by COMPACT and lack of evidence of carcinogenicity in the mouse bioassay. Hazardexpert predicts mutagenicity.
26. p-Nitrobenzoic acid. p-Nitrobenzoic acid is positive in COMPACT for P4501 and for P4502E but is rapidly metabolized by reduction and conjugation, probably resulting in little carcinogenicity. The rodent assay shows some evidence of carcinogenicity in female rat only (1/4 segments), which is in concordance with the COMPACT prediction. Hazardexpert predicts strong carcinogenicity. The p-carboxyl group, being electron withdrawing, will stabilize the nitrenium ion formed during metabolism of the nitro group, which contrasts with p-nitrophenol (no. 9) where the p-hydroxyl group is electron donating, and destabilizes the nitrenium ion so that carcinogenicity does not result.
27. Sodium azide. Sodium azide is a direct-acting mutagen. The related compound, hydrazoic acid, was negative for P4501 in COMPACT. Although having the structural criteria for P4502E, hydrazoic acid is unlikely to generate ROS (AE = 16.2).
Thus, the predictions C1 and CE for COM-PACT are negative, in concordance with the rat study which showed no carcinogenicity.
28. Tris(2-chloroethyl)phosphate. COMPACT is negative for both P4501 and P4502E, but it is probably direct-acting via the 2-chloroethyl (mustard) group. Clear evidence of carcinogenicity in the mouse means that there is no concordance with COMPACT. Hazardexpert predicts a weak carcinogen.
29. CI Direct blue 218. This chemical is positive for P4501 in COMPACT and is likely to undergo microbial azo reduction to form planar (carcinogenic) metabolites. The COMPACT prediction is in agreement with the rodent assay, which was clearly positive. Hazardexpert predicts marked carcinogenicity.
30. CI Pigment red 3. Another azo compound like the previous chemical, CI pigment red 3 is similarly predicted by COMPACT to be positive for P4501 and therefore carcinogenic. This prediction of carcinogenicity by COMPACT is in agreement with the rodent assay which shows carcinogenicity in 3/4 segments. Hazardexpert predicts strong carcinogenicity.
31. CI Pigment red 23. This azo dye is also P4501 positive in COMPACT, but there is equivocal evidence of carcinogenicity in only 1/4 segments in the rodent assay, probably due to the polarity of the compound and its ease of detoxication. However, following further details of the rodent pathology, this chemical is considered to be a weakly positive carcinogen. COMPACT prediction is therefore in concordance with the rodent assay. Hazardexpert predicts strong carcinogenicity. findings for P4501 and P4502E in COM-PACT are in agreement with the known lethal hepatotoxicity and nephrotoxicity. 34. Salicylazosulfapyridine. This compound is positive for P4501 in COM-PACT, and is consequently predicted to be a carcinogen. The rodent carcinogenicity tests are incomplete, so it is not possible to confirm this result, but this drug is known to be cytotoxic and to cause male infertility in humans (25) 3 ,3'-Dimethylbenzidine is positive for P4501 specificity in COMPACT and was thus predicted to be carcinogenic. This is in complete agreement with the carcinogenicity seen in the rat assay; no data are available for mouse. Hazardexpert predicts teratogenicity but not carcinogenicity.
41. HC Yellow 4. This compound was originally weakly positive for P4501 in COMPACT, but the chemical structure was incorrectly given. A reevaluation of the correct structure revealed that it was negative in COMPACT, which is in agreement with the rodent assay that was equivocal in one segment only and negative in the remaining three. Hazardexpert predicts strong carcinogenicity.
42. p-Nitroaniline. p-Nitroaniline is positive for P4501 and probably P4502E, and the COMPACT prediction is that it is carcinogenic. This compound was not evaluated for carcinogenicity in the rat and gave an equivocal result in the mouse. Further detail on the pathology indicates that it should be regarded as weakly positive, indicating concordance with the COMPACT prediction. Hazardexpert predicts strong carcinogenicity.
43. o-Nitroanisole. o-Nitroanisole is positive for P4501 and also P4502E in COMPACT, which predicts its carcinogenicity. Clear evidence of carcinogenicity in three segments of the rodent assay, and some evidence in the fourth, is in agreement with the COMPACT prediction. Hazardexpert predicts strong carcinogenicity.
44. 1,2,3-Trichloropropane. Although negative for P4501 specificity, this chemical is clearly a P4502E substrate with likely activation to form ROS. This indicates potential rodent carcinogenicity, which is in agreement with the rodent assay that showed carcinogenicity in all four segments. There is therefore positive concordance between the biological assay and the COMPACT prediction. Hazardexpert predicts strong carcinogenicity.
In summary, the concordance of COM-PACT (C) predictions with the rodent carcinogenicity assay is 72%, and for COM-PACT (CO) plus Hazardexpert, the concordance is 86%.
Discussion
At the National Institute of Environmental Health Sciences international workshop, Predicting Chemical Carcinogenesis in Rodents, held in May 1993, the importance of metabolism and the need for an understanding of the mechanisms of carcinogenicity were emphasized. The key roles of certain cytochromes P450 in the metabolic activation of many chemical carcinogens is well established (12, 26) , and these have been addressed in the COM-PACT study. The COMPACT (28) from their amino acid sequences, enabling the structural basis of ligand binding interactions to be explored. Although the Ah receptor has not yet been sequenced, COMPACT is able to identify its potential ligands because they are inducers of cytochrome P4501 and bear molecular characteristics common to P4501 substrates. Moreover, molecular modeling of entire P450 proteins associated with xenobiotic metabolism has been undertaken, based on sequence homology with the bacterial form of P450, which is of known crystal structure (29) . The putative active I., sites of these enzymes are considerably complementary to their specific substrates, and such studies will inevitably lead to further developments in COMPACT.
In conclusion, this study has shown that original COMPACT, based solely on CYPI specificity, is 64% predictive of rodent carcinogenicity in the 36 chemicals tested. COMPACT that includes CYP2E specificity in addition to CYPI specificity improves the concordance to 72%. This takes into account the possibility of carcinogenicity produced directly from the generation of reactive oxygen species (ROS) mediated by P4502E and the formation of reactive intermediates from the activation of the chemicals by these ROS (12) . The sensitivity of COMPACT (CYP1 and CYP2E) is 75%, and its positive predictivity is 75% (Table  5) . Furthermore, structural criteria for other P450 substrate specificity, and for associated receptors, should increase the scope of the technique. However, it would be advantageous to combine COMPACT with a structural alert program such as Hazardexpert, especially as this gives the added advantage of calculating logP and pI § values. We have shown that such a combination increases concordance with the rodent assay from 72% to 86% (Table 5 ). Four out of five of those chemicals that were incorrectly assigned by COMPACT in combination with Hazardexpert were predicted successfully by a combination of other methods (mutagenicity, structural alert, rodent chronic toxicity data) (22) , which indicates that a battery of short term tests could provide a favorable comparison with rodent carcinogenicity (19, 20, (30) (31) (32) .
